Search Results
Your search for ,iII matches 9386 pages
Showing 1401 - 1450
David H. Harpole, Jr, MD, on Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC
David H. Harpole, Jr, MD, of Duke University Medical Center, discusses further exploratory analyses of patients with EGFR-mutated resectable non–small cell lung cancer (NSCLC) enrolled in the phase III AEGEAN study. In this trial, perioperative durvalumab plus neoadjuvant chemotherapy, vs...
Ticiana A. Leal, MD, on Tumor Treating Fields and Immune Checkpoint Inhibition in Metastatic NSCLC
Ticiana A. Leal, MD, of Winship Cancer Institute at Emory University, discusses phase III findings from the LUNAR study of tumor treating fields (electric fields that disrupt cellular processes and lead to cell death) combined with the standard of care in patients with metastatic non–small cell...
Ambulatory Thromboprophylaxis in Patients With Lung and Gastrointestinal Cancers
In an Australian phase III trial (TARGET-TP) reported in JAMA Oncology, Alexander et al found that ambulatory thromboprophylaxis reduced the risk of thromboembolic events in patients starting systemic therapy for lung or gastrointestinal cancer who were at elevated risk of thrombosis. Study ...
Quality of Life With Nivolumab Plus Chemotherapy in Advanced Gastric/GEJ Cancer or Esophageal Adenocarcinoma
As reported in the Journal of Clinical Oncology, Markus Moehler, MD, and colleagues found that in the phase III CheckMate 649 trial, the addition of nivolumab to chemotherapy was associated with generally better patient-reported health-related quality of life outcomes in patients with advanced...
Addition of Hyperthermic Intraperitoneal Chemotherapy to Interval Cytoreductive Surgery in Advanced Ovarian Cancer
As reported in The Lancet Oncology by Aronson et al, the final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall ...
Neoadjuvant Chemotherapy Followed by Surgery vs Standard Chemoradiation for Cervical Cancer
In the phase III EORTC-55994 trial reported in the Journal of Clinical Oncology, Kenter et al found no significant difference in overall survival with neoadjuvant chemotherapy followed by surgery vs standard concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical cancer. Study...
Adjuvant Pemetrexed/Cisplatin vs Vinorelbine/Cisplatin in Stage II–IIIA Nonsquamous NSCLC
In a 5-year analysis of the Japanese phase III JIPANG trial reported in the Journal of Clinical Oncology, Kenmotsu et al found no significant differences in overall or recurrence-free survival with adjuvant pemetrexed/cisplatin vs vinorelbine/cisplatin in patients with stage II–IIIA nonsquamous...
Magrolimab Plus Azacitidine in Previously Untreated Patients With AML Ineligible for Intensive Chemotherapy
In a phase Ib study reported in the Journal of Clinical Oncology, Naval G. Daver, MD, and colleagues found that the combination of the anti-CD47 antibody magrolimab and azacitidine was active in previously untreated patients with acute myeloid leukemia (AML) who were ineligible for intensive...
More on Renal Cell Carcinoma From ASCO 2023: Focus on Atezolizumab Plus Cabozantinib vs Cabozantinib Alone
The addition of the monoclonal antibody atezolizumab to the tyrosine kinase inhibitor cabozantinib failed to improve progression-free survival and overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma (previously treated with an immune checkpoint inhibitor) in the...
Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting
The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...
HERTHENA-Lung01: Patritumab Deruxtecan for Advanced EGFR-Mutant NSCLC
In the phase II HERTHENA-Lung01 trial reported in the Journal of Clinical Oncology, Helena Yu, MD, and colleagues found that patritumab deruxtecan (HER3-DXd), a new anti-HER3 antibody-drug conjugate, showed activity in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC)...
Understanding the Treatment of Waldenström’s Macroglobulinemia
Waldenström’s macroglobulinemia is a rare and incurable low-grade B-cell lymphoproliferative disease defined by specific genotypic subtypes that have implications for treatment response and long-term outcomes. Treatment—and there is no established standard—is mainly focused on controlling symptoms...
NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC
The anti–PD-L1 monoclonal antibody durvalumab in combination with other immuno-oncology agents may outperform treatment with durvalumab alone in the neoadjuvant setting for patients with early-stage non–small cell lung cancer (NSCLC), according to a recent study published by Cascone et al in Cancer ...
First-Line NALIRIFOX vs Nab-paclitaxel/Gemcitabine in Metastatic Pancreatic Cancer: NAPOLI-3
As reported in The Lancet by Zev A. Wainberg, MD, and colleagues, the phase III NAPOLI-3 trial has shown a modest but significant improvement in overall survival with first-line NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil) vs nab-paclitaxel and gemcitabine in patients ...
Effect of Diet and Exercise Intervention on Chemotherapy Dose Intensity, Response Rate Among Patients With Breast Cancer
In the LEANer study, reported in the Journal of Clinical Oncology by Tara Sanft, MD, and colleagues, researchers found that an exercise and nutrition intervention did not improve relative dose intensity (RDI) among patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer, but did...
Addition of Olaparib to Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Overall Survival Results in the PROpel Trial
As reported by Fred Saad, MD, and colleagues in The Lancet Oncology, the final prespecified overall survival analysis of the phase III PROpel trial showed no significant benefit with the addition of first-line olaparib to abiraterone in patients with metastatic castration-resistant prostate cancer...
Effect of Adjuvant Metformin on Risk of New Primary Cancers in Patients With Early Breast Cancer
In an analysis from the Canadian Cancer Trials Group MA.32 study reported in the Journal of Clinical Oncology, Pamela Goodwin, MD, MSc, FRCPC, FASCO, and colleagues found that adjuvant metformin did not reduce the risk of new primary invasive cancers vs placebo in patients with early breast cancer. ...
Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab
In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodrug, to nivolumab did not improve treatment outcomes in previously untreated patients with advanced...
Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer
In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib, nivolumab, and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) showed activity as a first-line treatment regimen for patients with HER2-negative metastatic...
FDA Approves Momelotinib for Patients With Myelofibrosis and Anemia
On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post–polycythemia vera and post–essential thrombocythemia), in adults with anemia....
Comparing Radiation Therapies for NSCLC
Intensity-modulated radiation therapy may be the preferred treatment option for patients with locally advanced non–small cell lung cancer (NSCLC), according to findings presented by Chun et al at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer ...
Extensive-Stage Small Cell Lung Cancer: Triplet Combination vs Chemotherapy Alone
The combination of benmelstobart, anlotinib, and chemotherapy may be effective at improving median progression-free survival and overall survival in patients with extensive-stage small cell lung cancer compared with placebo and chemotherapy, according to findings presented by Cheng et al at the...
Is Adagrasib Active in KRAS G12C–Mutated NSCLC?
The oral KRAS G12C inhibitor adagrasib may offer durable clinical activity, with a median overall survival of 14.1 months and a 2-year survival rate of about 33%, in patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to findings presented by Gadgeel et al at the...
Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer
In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) was associated with improved patient-reported swallowing function vs standard IMRT in newly diagnosed patients with head and neck cancer. Study...
Expert Point of View: Priyanka Bhateja, MD
Head and neck cancer specialist Priyanka Bhateja, MD, Assistant Professor in the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, was encouraged by the findings of the Quarterback trial. As she noted in her comments for The ASCO Post, human papillomavirus...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
Expert Point of View: Barbara Burtness, MD
Discussing this study in her Highlights of the Day at the 2023 ASCO Annual Meeting was Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, Connecticut. She noted that the premise of the FRAIL-IMMUNE trial...
For Advanced Nasopharyngeal Cancer, Adjuvant Gemcitabine Plus Cisplatin Favored Over Fluorouracil Plus Cisplatin, Study Reports
In patients with N2 and N3 nasopharyngeal carcinoma, adjuvant treatment with concurrent gemcitabine and cisplatin significantly improved progression-free survival, with acceptable toxicity, over fluorouracil plus cisplatin, according to a phase III trial reported from Sun Yat-sen University Cancer...
CONTINUUM: In Locally Advanced Nasopharyngeal Cancer, Addition of Sintilimab to Chemoradiotherapy Offers Benefit
The addition of the PD-1 inhibitor sintilimab to standard induction chemotherapy and chemoradiotherapy resulted in a significant improvement in 3-year event-free survival, a manageable safety profile, and comparable quality of life in high-risk, locally advanced nasopharyngeal carcinoma vs standard ...
Head and Neck Cancers 2022–2023 Almanac
Head and neck cancers comprise approximately 4% of all new cancer diagnoses globally and represent approximately 110,000 new cancer diagnoses and 17,000 cancer deaths annually in the United States. Head and neck cancers are a heterogenous group of malignancies where prognosis and treatment varies...
First-in-Class Agent Given With Chemoradiotherapy Improves Survival in Locally Advanced Head and Neck Cancer, Study Finds
The first-in-class agent xevinapant (also known as Debio 1143), given with chemotherapy and radiotherapy, significantly improved overall survival in a phase II study of 96 patients with locally advanced squamous cell carcinoma of the head and neck.1 “This is the first study in decades to improve...
Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Pembrolizumab Plus Chemoradiation Therapy Falls Short in Locally Advanced Head and Neck Cancer
Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head and neck squamous cell carcinoma, but favorable numerical trends were demonstrated, according to...
Selinexor Maintenance Therapy in Advanced or Recurrent Endometrial Cancer
In a phase III study (ENGOT-EN5/GOG-3055/SIENDO) reported in the Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, and colleagues found that a progression-free survival benefit with maintenance selinexor vs placebo after first-line chemotherapy in patients with advanced or recurrent...
AEGEAN Trial: Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy in Resectable NSCLC
The addition of perioperative durvalumab to neoadjuvant chemotherapy may be associated with a tolerable surgical safety profile and may not adversely impact surgery in patients with resectable non–small cell lung cancer (NSCLC), according to new findings presented by Mitsudomi et al at the...
KRAS Wild-Type Advanced Pancreatic Cancer: Addition of Monoclonal Antibody to Chemotherapy
In the Chinese phase III NOTABLE trial reported in the Journal of Clinical Oncology, Shukui Qin, MD, and colleagues examined the addition of the EGFR inhibitor nimotuzumab to gemcitabine in patients with KRAS wild-type locally advanced or metastatic pancreatic cancer. Study Details In the...
FDA Approves New Multiple Myeloma Combination Therapy
On September 11, the U.S. Food and Drug Administration (FDA) approved motixafortide (Aphexda) in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Motixafortide is...
NSCLC: Osimertinib Plus Chemo vs Osimertinib Alone
Osimertinib plus chemotherapy may have demonstrated a statistically significant and clinically meaningful progression-free survival benefit in patients with advanced non–small cell lung cancer (NSCLC) compared with osimertinib alone, according to new findings presented by Jänne et al at the...
EGFR Tyrosine Kinase Inhibitors vs Durvalumab in EGFR-Mutated NSCLC: Impact on Survival
Researchers have discovered that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors may improve survival outcomes after treatment with chemoradiation in patients with stage III EGFR-mutated non–small cell lung cancer (NSCLC) compared to the PD-L1 inhibitor durvalumab, according to...
Incremental Gains Toward Better Outcomes in Small Cell Lung Cancer
Novel treatments beyond the current chemoimmunotherapies are offering more treatment options in small cell lung cancer (SCLC), though real breakthroughs remain elusive, according to Ticiana Leal, MD, Associate Professor in the Department of Hematology and Medical Oncology, Emory University School...
More on Treatments Under Study in NSCLC From ASCO 2023
Two phase III trials presented at the 2023 ASCO Annual Meeting explored treatments under study for patients with non–small cell lung cancer (NSCLC). In an exploratory analysis of the CodeBreaK 200 trial, the KRAS inhibitor sotorasib was compared with docetaxel chemotherapy in subsets of patients...
More on Melanoma From ASCO 2023: Focus on Two Different Treatment Strategies
In patients with melanoma who are undergoing neoadjuvant therapy with immune checkpoint blockade, response to treatment may guide the intensity of additional treatment, according to a retrospective analysis of two major trials presented by Irene L.M. Reijers, an MD/PhD candidate in the Christian...
Study Shows Benefit With Addition of Tumor Treating Fields Therapy in Metastatic Non–Small Cell Lung Cancer
Tumor treating fields (TTF) therapy in combination with immune checkpoint inhibition improved overall survival in the pretreated, primarily immunotherapy-naive setting in metastatic non–small cell lung cancer (NSCLC), according to findings from the phase III LUNAR study. These results were...
Predicting Recurrence in Colorectal Cancer Using Postoperative Circulating Tumor DNA Dynamics
Postoperative molecular residual disease detected by circulating tumor DNA (ctDNA) at 4 weeks after resection has emerged as the strongest prognostic risk factor for disease-free survival in patients with resected colorectal cancer. This finding was observed regardless of BRAF V600E status and...
Rising After Struggle: Surviving My First ASCO Breakthrough in Japan
After a year of hard work preparing a strong abstract for the prestigious 2023 ASCO Annual Meeting, I finally received an acceptance letter from the scientific committee. I was overjoyed to see the efforts of our multinational team being rewarded. A few moments later, I received the decision...
Thomas J. Herzog, MD, Takes Office as President of the GOG Foundation, Inc
Thomas J. Herzog, MD, took office as President of the GOG Foundation (GOG-F, formerly the Gynecologic Oncology Group), Inc, on July 20, 2023, at the NRG Oncology Summer Meeting. Former GOG-F President, Larry J. Copeland, MD, passed the presidential gavel to Dr. Herzog at the GOG-F Board of...
Addition of Nivolumab to Stereotactic Ablative Radiotherapy in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In a phase II trial (I-SABR) reported in The Lancet, Joe Y. Chang, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the addition of immunotherapy with nivolumab to stereotactic ablative radiotherapy (SABR) improved ...
Expert Point of View: Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, FACP, FASCO, the David H. Johnson Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, commented that the...
LEAP-017: No Significant Benefit for Lenvatinib Plus Pembrolizumab in Non–MSI-H/dMMR Metastatic Colorectal Cancer
In the final analysis of the phase III LEAP-017 study, the combination of lenvatinib plus pembrolizumab failed to improve outcomes over the standard of care in previously treated patients with metastatic colorectal cancer that lacked high microsatellite instability or mismatch repair deficiency...
Selinexor Shows Activity as Maintenance Therapy for TP53 Wild-Type Endometrial Cancer in Phase III Trial
Long-term follow-up of selinexor maintenance therapy has demonstrated promising efficacy in patients with TP53 wild-type endometrial cancer, according to data presented during the ASCO Plenary Series: July 2023 Session.1 Selinexor is a selective inhibitor of nuclear export (SINE) approved for use...
